Here, we performed a holistic assessment of the expression frequency of PD-L1 in tumor and tumor-infiltrating immune cells (CD4+, CD8+, and FoxP3+ T cells and CD163+ macrophages) to get a comprehensive landscape of the TIME in PESCC and provide practicable markers for patient enrollment in future clinical trials. The gene discussed is CD163; the disease is neoplasm.